Divis Laboratories Ltd

Divi's Lab. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Divis Laboratories Ltd

₹ 6,168 -0.27%
13 Feb - close price
divislabs.com BSE: 532488 NSE: DIVISLAB
About

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]

Key Points

Business Overview:[1]
Company manufactures Generic Active pharmaceuticals ingredients, Custom synthesis of APIs & Intermediates along with Nutraceuticals for Global Pharmaceutical & Nutraceutical industry. These are segmented as:
a) Generic APIs:[2]
Company manufactures 30 Large Volume Generic APIs in 10’s to 100’s/1000’s of Tons each year and exports them to 100+ countries. Further, there are 10 APIs in various stages of R&D and pilot scale development
b) Custom Synthesis:[3]
Company under Custom Synthesis of APIs and Intermediates for global companies with a portfolio of products across diverse therapeutic areas. 12 out of top 20 Big Pharma Companies across US, EU and Japan have been associated with Divi’s for 10+ years
c) Nutraceutical:[4][5]
Company's Vishakhapatnam unit produces active ingredient and finished forms of Carotenoids. It is currently supplying carotenoids to all major food, dietary supplement and feed manufacturers globally. Company also offers customized ingredient solutions in liquids, beadlets and powder forms

Website BSE NSE
  • Market Cap ₹ 1,63,754 Cr.
  • Current Price ₹ 6,168
  • High / Low ₹ 7,078 / 4,942
  • Stock P/E 64.6
  • Book Value ₹ 581
  • Dividend Yield 0.49 %
  • ROCE 20.4 %
  • ROE 15.4 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 43.2%

Cons

  • Stock is trading at 10.6 times its book value
  • The company has delivered a poor sales growth of 11.6% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 100 BSE 200 BSE Dollex 200

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
1,708 1,951 1,778 1,909 1,855 2,303 2,118 2,338 2,319 2,585 2,410 2,715 2,604
1,299 1,464 1,274 1,430 1,366 1,572 1,496 1,622 1,576 1,699 1,681 1,827 1,714
Operating Profit 409 487 504 479 489 731 622 716 743 886 729 888 890
OPM % 24% 25% 28% 25% 26% 32% 29% 31% 32% 34% 30% 33% 34%
113 66 81 86 95 79 79 106 82 86 119 145 14
Interest 0 0 0 1 0 2 0 1 0 1 3 8 6
Depreciation 87 87 93 95 95 95 97 99 99 107 112 113 118
Profit before tax 435 466 492 469 489 713 604 722 726 864 733 912 780
Tax % 30% 31% 28% 26% 27% 25% 29% 29% 19% 23% 26% 24% 25%
306 321 356 348 358 538 430 510 589 662 545 689 583
EPS in Rs 11.53 12.09 13.41 13.11 13.49 20.27 16.20 19.21 22.19 24.94 20.53 25.95 21.96
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
2,532 3,115 3,776 4,064 3,891 4,946 5,394 6,969 8,960 7,768 7,845 9,360 10,314
1,514 1,942 2,354 2,615 2,622 3,072 3,568 4,102 5,075 5,397 5,635 6,387 6,921
Operating Profit 1,018 1,173 1,423 1,450 1,269 1,874 1,826 2,867 3,885 2,370 2,210 2,973 3,393
OPM % 40% 38% 38% 36% 33% 38% 34% 41% 43% 31% 28% 32% 33%
68 38 93 72 107 154 186 57 112 344 335 348 364
Interest 3 3 5 3 2 5 7 2 2 2 4 3 18
Depreciation 92 136 118 123 142 169 186 256 312 343 378 402 450
Profit before tax 991 1,072 1,393 1,395 1,231 1,855 1,819 2,666 3,684 2,369 2,163 2,916 3,289
Tax % 22% 21% 19% 24% 29% 27% 24% 26% 20% 23% 26% 25%
773 852 1,126 1,060 877 1,353 1,377 1,984 2,960 1,823 1,600 2,191 2,479
EPS in Rs 29.13 32.07 42.41 39.95 33.04 50.96 51.85 74.75 111.52 68.69 60.27 82.53 93.38
Dividend Payout % 34% 31% 24% 25% 30% 31% 31% 27% 27% 44% 50% 36%
Compounded Sales Growth
10 Years: 12%
5 Years: 12%
3 Years: 1%
TTM: 14%
Compounded Profit Growth
10 Years: 10%
5 Years: 10%
3 Years: -10%
TTM: 23%
Stock Price CAGR
10 Years: 20%
5 Years: 11%
3 Years: 30%
1 Year: 6%
Return on Equity
10 Years: 19%
5 Years: 18%
3 Years: 14%
Last Year: 15%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 27 27 53 53 53 53 53 53 53 53 53 53 53
Reserves 2,937 3,469 4,240 5,304 5,872 6,904 7,257 9,242 11,675 12,714 13,518 14,916 15,360
18 27 42 36 63 106 39 5 4 3 3 4 90
729 883 562 762 797 973 1,183 1,471 1,628 1,654 1,886 1,948 2,648
Total Liabilities 3,710 4,405 4,898 6,155 6,785 8,036 8,531 10,771 13,360 14,425 15,460 16,921 18,151
1,222 1,309 1,439 1,559 1,996 2,088 2,782 3,704 4,325 4,723 4,739 5,442 5,678
CWIP 144 218 264 444 120 492 920 711 470 212 778 1,022 2,030
Investments 502 733 803 1,631 1,889 1,946 971 0 72 77 82 65 67
1,842 2,145 2,392 2,521 2,780 3,511 3,858 6,356 8,493 9,413 9,861 10,392 10,376
Total Assets 3,710 4,405 4,898 6,155 6,785 8,036 8,531 10,771 13,360 14,425 15,460 16,921 18,151

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
557 826 1,038 1,150 776 954 1,216 1,947 1,912 2,460 1,261 1,653
-305 -521 -406 -1,140 -478 -685 -83 75 -2,195 -2,708 -269 -804
-248 -303 -631 2 -314 -246 -1,091 -35 -532 -797 -799 -799
Net Cash Flow 3 3 0 13 -17 23 41 1,987 -816 -1,045 193 50

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 104 87 85 81 95 86 96 88 99 84 100 106
Inventory Days 372 350 293 307 314 347 316 329 341 352 364 311
Days Payable 61 68 56 104 96 96 100 117 96 89 94 88
Cash Conversion Cycle 416 368 322 284 313 336 312 300 344 347 370 330
Working Capital Days 157 140 158 147 176 169 180 152 177 188 206 192
ROCE % 36% 33% 36% 29% 22% 29% 25% 32% 35% 19% 16% 20%

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
51.94% 51.93% 51.93% 51.92% 51.92% 51.89% 51.89% 51.89% 51.89% 51.88% 51.88% 51.88%
14.67% 14.69% 14.60% 14.85% 14.68% 16.16% 17.25% 17.98% 18.01% 19.74% 19.39% 20.08%
21.00% 21.15% 21.65% 21.78% 22.10% 21.66% 20.98% 20.44% 20.63% 18.96% 19.68% 19.18%
0.07% 0.10% 0.10% 0.10% 0.10% 0.10% 0.09% 0.09% 0.09% 0.09% 0.09% 0.09%
12.31% 12.13% 11.72% 11.33% 11.19% 10.17% 9.79% 9.58% 9.39% 9.32% 8.96% 8.75%
No. of Shareholders 4,33,6214,02,1553,73,8603,54,4823,47,6292,98,3102,78,8992,80,6012,67,7552,59,8252,49,6342,33,844

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls